Xeris Pharmaceuticals
Company Profile
Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm | 63.60 mm |
Cash burn (monthly) | 1.00 mm | 3.24 mm | 8.60 mm | 6.30 mm | 6.67 mm | 5.99 mm |
Cash used (since last report) | 46.57 mm | 150.58 mm | 399.63 mm | 292.95 mm | 310.29 mm | 278.30 mm |
Cash remaining | 17.03 mm | -86.98 mm | -336.03 mm | -229.35 mm | -246.69 mm | -214.70 mm |
Runway (months of cash) | 17.0 | -26.9 | -39.1 | -36.4 | -37.0 | -35.9 |
13F holders | Current |
---|---|
Total holders | 162 |
Opened positions | 29 |
Closed positions | 12 |
Increased positions | 59 |
Reduced positions | 32 |
13F shares | Current |
---|---|
Total value | 216.59 bn |
Total shares | 74.49 mm |
Total puts | 21.70 k |
Total calls | 34.20 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 10.82 mm | $36.68 bn |
Vanguard | 7.90 mm | $26.78 bn |
Flynn James E | 5.88 mm | $17.24 mm |
Geode Capital Management | 3.35 mm | $11.36 bn |
STT State Street | 3.34 mm | $11.33 bn |
Sessa Capital | 3.26 mm | $0.00 |
Rosalind Advisors | 3.10 mm | $10.53 bn |
MS Morgan Stanley | 2.88 mm | $9.75 bn |
AIGH Capital Management | 2.57 mm | $8.73 bn |
Renaissance Technologies | 2.10 mm | $7.12 bn |